109 related articles for article (PubMed ID: 20088807)
41. PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo.
Okuda M; Hijikuro I; Fujita Y; Wu X; Nakayama S; Sakata Y; Noguchi Y; Ogo M; Akasofu S; Ito Y; Soeda Y; Tsuchiya N; Tanaka N; Takahashi T; Sugimoto H
PLoS One; 2015; 10(2):e0117511. PubMed ID: 25659102
[TBL] [Abstract][Full Text] [Related]
42. Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.
Reynolds MR; Reyes JF; Fu Y; Bigio EH; Guillozet-Bongaarts AL; Berry RW; Binder LI
J Neurosci; 2006 Oct; 26(42):10636-45. PubMed ID: 17050703
[TBL] [Abstract][Full Text] [Related]
43. Tau oligomers as potential targets for early diagnosis of tauopathy.
Sahara N; Ren Y; Ward S; Binder LI; Suhara T; Higuchi M
J Alzheimers Dis; 2014; 40 Suppl 1():S91-6. PubMed ID: 24595194
[TBL] [Abstract][Full Text] [Related]
44. Potentiating tangle formation reduces acute toxicity of soluble tau species in the rat.
d'Orange M; Aurégan G; Cheramy D; Gaudin-Guérif M; Lieger S; Guillermier M; Stimmer L; Joséphine C; Hérard AS; Gaillard MC; Petit F; Kiessling MC; Schmitz C; Colin M; Buée L; Panayi F; Diguet E; Brouillet E; Hantraye P; Bemelmans AP; Cambon K
Brain; 2018 Feb; 141(2):535-549. PubMed ID: 29253129
[TBL] [Abstract][Full Text] [Related]
45. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy.
Mocanu MM; Nissen A; Eckermann K; Khlistunova I; Biernat J; Drexler D; Petrova O; Schönig K; Bujard H; Mandelkow E; Zhou L; Rune G; Mandelkow EM
J Neurosci; 2008 Jan; 28(3):737-48. PubMed ID: 18199773
[TBL] [Abstract][Full Text] [Related]
46. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
Giacomini C; Koo CY; Yankova N; Tavares IA; Wray S; Noble W; Hanger DP; Morris JDH
Acta Neuropathol Commun; 2018 May; 6(1):37. PubMed ID: 29730992
[TBL] [Abstract][Full Text] [Related]
47. Pseudo-phosphorylation of tau at Ser202 and Thr205 affects tau filament formation.
Rankin CA; Sun Q; Gamblin TC
Brain Res Mol Brain Res; 2005 Jul; 138(1):84-93. PubMed ID: 15913837
[TBL] [Abstract][Full Text] [Related]
48. Tau in aluminum-induced neurofibrillary tangles.
Singer SM; Chambers CB; Newfry GA; Norlund MA; Muma NA
Neurotoxicology; 1997; 18(1):63-76. PubMed ID: 9215989
[TBL] [Abstract][Full Text] [Related]
49. A complex mechanism for inducer mediated tau polymerization.
Carlson SW; Branden M; Voss K; Sun Q; Rankin CA; Gamblin TC
Biochemistry; 2007 Jul; 46(30):8838-49. PubMed ID: 17608454
[TBL] [Abstract][Full Text] [Related]
50. Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice.
Halverson RA; Lewis J; Frausto S; Hutton M; Muma NA
J Neurosci; 2005 Feb; 25(5):1226-33. PubMed ID: 15689560
[TBL] [Abstract][Full Text] [Related]
51. Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies.
Pickhardt M; Neumann T; Schwizer D; Callaway K; Vendruscolo M; Schenk D; St George-Hyslop P; Mandelkow EM; Dobson CM; McConlogue L; Mandelkow E; Tóth G
Curr Alzheimer Res; 2015; 12(9):814-28. PubMed ID: 26510979
[TBL] [Abstract][Full Text] [Related]
52. Targeted downregulation of dMyc restricts neurofibrillary tangles mediated pathogenesis of human neuronal tauopathies in Drosophila.
Chanu SI; Sarkar S
Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2111-2119. PubMed ID: 28529046
[TBL] [Abstract][Full Text] [Related]
53. Sources of extracellular tau and its signaling.
Avila J; Simón D; Díaz-Hernández M; Pintor J; Hernández F
J Alzheimers Dis; 2014; 40 Suppl 1():S7-S15. PubMed ID: 24531154
[TBL] [Abstract][Full Text] [Related]
54. Coenzyme q induces tau aggregation, tau filaments, and Hirano bodies.
Santa-Mara I; Santpere G; MacDonald MJ; Gomez de Barreda E; Hernandez F; Moreno FJ; Ferrer I; Avila J
J Neuropathol Exp Neurol; 2008 May; 67(5):428-34. PubMed ID: 18431254
[TBL] [Abstract][Full Text] [Related]
55. Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.
Congdon EE; Lin Y; Rajamohamedsait HB; Shamir DB; Krishnaswamy S; Rajamohamedsait WJ; Rasool S; Gonzalez V; Levenga J; Gu J; Hoeffer C; Sigurdsson EM
Mol Neurodegener; 2016 Aug; 11(1):62. PubMed ID: 27578006
[TBL] [Abstract][Full Text] [Related]
56. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
Wang JZ; Grundke-Iqbal I; Iqbal K
Eur J Neurosci; 2007 Jan; 25(1):59-68. PubMed ID: 17241267
[TBL] [Abstract][Full Text] [Related]
57. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
[TBL] [Abstract][Full Text] [Related]
58. Tau in paired helical filaments is functionally distinct from fetal tau: assembly incompetence of paired helical filament-tau.
Yoshida H; Ihara Y
J Neurochem; 1993 Sep; 61(3):1183-6. PubMed ID: 8360683
[TBL] [Abstract][Full Text] [Related]
59. Pathological tau: a loss of normal function or a gain in toxicity?
Trojanowski JQ; Lee VM
Nat Neurosci; 2005 Sep; 8(9):1136-7. PubMed ID: 16127446
[No Abstract] [Full Text] [Related]
60. Tau and axonopathy in neurodegenerative disorders.
Higuchi M; Lee VM; Trojanowski JQ
Neuromolecular Med; 2002; 2(2):131-50. PubMed ID: 12428808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
